Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient OutcomesBusiness Wire • 09/20/22
Exscientia plc (EXAI) CEO Andrew Hopkins on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/18/22
Exscientia to Report Second Quarter 2022 Financial Results on August 17, 2022Business Wire • 08/10/22
Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 63%: Read This Before Placing a BetZacks Investment Research • 06/16/22
Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy VolunteersBusiness Wire • 06/14/22
Exscientia to Present at the Goldman Sachs 43rd Annual Global Healthcare ConferenceBusiness Wire • 06/07/22
Exscientia plc (EXAI) CEO Andrew Hopkins on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/26/22
Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022Business Wire • 04/08/22
Exscientia plc (EXAI) CEO Andrew Hopkins on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/24/22
Exscientia to Report Fourth Quarter and Year End 2021 Financial Results on March 23, 2022Business Wire • 03/16/22
Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug DiscoveryBusiness Wire • 03/10/22
Exscientia to Highlight Precision Medicine Platform and Pipeline Data at the American Association of Cancer Research Annual Meeting 2022Business Wire • 03/08/22
Is Exscientia PLC Sponsored ADR (EXAI) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/09/22
Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AIBusiness Wire • 01/19/22